331 related articles for article (PubMed ID: 21106849)
1. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR
J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800
[TBL] [Abstract][Full Text] [Related]
3. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
Cohen AD; Diab A; Perales MA; Wolchok JD; Rizzuto G; Merghoub T; Huggins D; Liu C; Turk MJ; Restifo NP; Sakaguchi S; Houghton AN
Cancer Res; 2006 May; 66(9):4904-12. PubMed ID: 16651447
[TBL] [Abstract][Full Text] [Related]
4. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
5. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
Coe D; Begom S; Addey C; White M; Dyson J; Chai JG
Cancer Immunol Immunother; 2010 Sep; 59(9):1367-77. PubMed ID: 20480365
[TBL] [Abstract][Full Text] [Related]
6. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity.
Cho JS; Hsu JV; Morrison SL
Cancer Immunol Immunother; 2009 Jul; 58(7):1057-69. PubMed ID: 19018533
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells.
Ronchetti S; Nocentini G; Bianchini R; Krausz LT; Migliorati G; Riccardi C
J Immunol; 2007 Nov; 179(9):5916-26. PubMed ID: 17947665
[TBL] [Abstract][Full Text] [Related]
8. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease.
Muriglan SJ; Ramirez-Montagut T; Alpdogan O; Van Huystee TW; Eng JM; Hubbard VM; Kochman AA; Tjoe KH; Riccardi C; Pandolfi PP; Sakaguchi S; Houghton AN; Van Den Brink MR
J Exp Med; 2004 Jul; 200(2):149-57. PubMed ID: 15249593
[TBL] [Abstract][Full Text] [Related]
9. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
10. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells.
Kanamaru F; Youngnak P; Hashiguchi M; Nishioka T; Takahashi T; Sakaguchi S; Ishikawa I; Azuma M
J Immunol; 2004 Jun; 172(12):7306-14. PubMed ID: 15187106
[TBL] [Abstract][Full Text] [Related]
11. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
Zhou P; L'italien L; Hodges D; Schebye XM
J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180
[TBL] [Abstract][Full Text] [Related]
12. Conversion of alloantigen-specific CD8+ T cell anergy to CD8+ T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor.
Kim J; Choi WS; Kang H; Kim HJ; Suh JH; Sakaguchi S; Kwon B
J Immunol; 2006 May; 176(9):5223-31. PubMed ID: 16621987
[TBL] [Abstract][Full Text] [Related]
13. In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1.
La S; Kim E; Kwon B
Exp Mol Med; 2005 Jun; 37(3):193-8. PubMed ID: 16000873
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
15. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
16. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
Shevach EM; Stephens GL
Nat Rev Immunol; 2006 Aug; 6(8):613-8. PubMed ID: 16868552
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells.
Lee SK; Choi BK; Kim YH; Kang WJ; Kim KH; Sakaguchi S; Suh JH; Kim TY; Kwon BS
Immunology; 2006 Dec; 119(4):479-87. PubMed ID: 17177830
[TBL] [Abstract][Full Text] [Related]
18. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
[TBL] [Abstract][Full Text] [Related]
19. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
20. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
